
Johnson & Johnson Acquires Intra-Cellular Pharmaceuticals
The deal boosts J&J's position in neurology, with Caplyta at the forefront of their mood disorder treatments.
Arthur is an experienced stock trader with a keen eye for market dynamics. Outside of trading, he passionately explores British literature and history.
The deal boosts J&J's position in neurology, with Caplyta at the forefront of their mood disorder treatments.
Thomas Tuchel as National Coach? Because Why Not?
A Fight Back into the Premier League